FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976431529> ?p ?o ?g. }

• W1976431529 endingPage "184" @default.
• W1976431529 startingPage "175" @default.
• W1976431529 abstract "Background:Bone metastases are common in patients with advanced breast cancer, and place patients at risk for skeletal-related events (SREs) including pathologic fracture, spinal cord compression, hypercalcemia of malignancy, and the need for radiotherapy and/or surgery to bone. These SREs are associated with reduced survival and quality-of-life. The nitrogen-containing bisphosphonates Zometa (zoledronic acid, ZOL) and Aredia (pamidronate disodium, PAM) reduce SRE risk in patients with bone metastases from breast cancer. This database analysis compared SRE and mortality rates in a real-life setting in women with breast cancer receiving ZOL and PAM, and assessed long-term ZOL benefit.Methods:A retrospective, claims-based analysis was conducted using commercial and Medicare Advantage data from >45 US managed-care plans. Eligible adult patients had diagnoses for breast cancer and bone metastasis between 01/01/01 and 12/31/06, continuous enrollment in the health plan, and no evidence of bone metastasis or intravenous bisphosphonate (IV-BP) use for 6 months before their first ZOL or PAM infusion. Patients were followed until disenrollment (including mortality) or end of the analysis period (12/31/07). Persistency was defined as absence of a >45-day gap between IV-BP treatments.Results:Of 8757 patients (mean age, 58.1 [SD 12.4] years), ∼ 30% were treated with ZOL, 15% with PAM, and 55% with no IV-BP. Patients treated with ZOL had a moderately lower incidence of SREs (mean, 36.2 vs 40.0 SREs/100 person-years; p = 0.0707) and significantly lower mortality (mean, 6.5 vs 11.2 deaths/100 person-years; p < 0.001) compared with PAM-treated patients. Longer persistency with ZOL was associated with lower risk of fracture and all SREs (trend-test p = 0.0076 and p = 0.0200, respectively).Limitations:Interpretation of this claims-based analysis must be tempered by the inherent limitations of observational data, such as imbalances in patient populations and the potential for bias in treatment selection.Conclusions:This analysis suggests that fewer than half of breast cancer patients with bone metastases receive IV-BPs. Longer persistence with ZOL was associated with lower SRE risk, and ZOL-treated patients had longer survival and a non-significant trend toward fewer SREs compared with PAM." @default.
• W1976431529 created "2016-06-24" @default.
• W1976431529 creator A5055552324 @default.
• W1976431529 creator A5056463375 @default.
• W1976431529 date "2011-11-08" @default.
• W1976431529 modified "2023-09-26" @default.
• W1976431529 title "Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan" @default.
• W1976431529 cites W1967568153 @default.
• W1976431529 cites W1967875617 @default.
• W1976431529 cites W1982915376 @default.
• W1976431529 cites W1991482135 @default.
• W1976431529 cites W1991668450 @default.
• W1976431529 cites W1995615104 @default.
• W1976431529 cites W2011926580 @default.
• W1976431529 cites W2021852492 @default.
• W1976431529 cites W2041868422 @default.
• W1976431529 cites W2048224440 @default.
• W1976431529 cites W2050358330 @default.
• W1976431529 cites W2073380111 @default.
• W1976431529 cites W2076073398 @default.
• W1976431529 cites W2077073060 @default.
• W1976431529 cites W2080918625 @default.
• W1976431529 cites W2091579635 @default.
• W1976431529 cites W2103011422 @default.
• W1976431529 cites W2104206635 @default.
• W1976431529 cites W2104518011 @default.
• W1976431529 cites W2115871403 @default.
• W1976431529 cites W2120080073 @default.
• W1976431529 cites W2141884093 @default.
• W1976431529 cites W2142234592 @default.
• W1976431529 cites W2143939516 @default.
• W1976431529 cites W2148096512 @default.
• W1976431529 cites W2148226416 @default.
• W1976431529 cites W2152409486 @default.
• W1976431529 cites W2161226294 @default.
• W1976431529 cites W2165011173 @default.
• W1976431529 doi "https://doi.org/10.3111/13696998.2011.632044" @default.
• W1976431529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22017235" @default.
• W1976431529 hasPublicationYear "2011" @default.
• W1976431529 type Work @default.
• W1976431529 sameAs 1976431529 @default.
• W1976431529 citedByCount "8" @default.
• W1976431529 countsByYear W19764315292013 @default.
• W1976431529 countsByYear W19764315292016 @default.
• W1976431529 countsByYear W19764315292017 @default.
• W1976431529 countsByYear W19764315292018 @default.
• W1976431529 countsByYear W19764315292020 @default.
• W1976431529 countsByYear W19764315292022 @default.
• W1976431529 crossrefType "journal-article" @default.
• W1976431529 hasAuthorship W1976431529A5055552324 @default.
• W1976431529 hasAuthorship W1976431529A5056463375 @default.
• W1976431529 hasBestOaLocation W19764315291 @default.
• W1976431529 hasConcept C118552586 @default.
• W1976431529 hasConcept C120665830 @default.
• W1976431529 hasConcept C121332964 @default.
• W1976431529 hasConcept C121608353 @default.
• W1976431529 hasConcept C126322002 @default.
• W1976431529 hasConcept C141071460 @default.
• W1976431529 hasConcept C143998085 @default.
• W1976431529 hasConcept C167135981 @default.
• W1976431529 hasConcept C2776326535 @default.
• W1976431529 hasConcept C2776541429 @default.
• W1976431529 hasConcept C2777251235 @default.
• W1976431529 hasConcept C2777783956 @default.
• W1976431529 hasConcept C2778231337 @default.
• W1976431529 hasConcept C2779013556 @default.
• W1976431529 hasConcept C2779399171 @default.
• W1976431529 hasConcept C2780775167 @default.
• W1976431529 hasConcept C530470458 @default.
• W1976431529 hasConcept C61511704 @default.
• W1976431529 hasConcept C71924100 @default.
• W1976431529 hasConceptScore W1976431529C118552586 @default.
• W1976431529 hasConceptScore W1976431529C120665830 @default.
• W1976431529 hasConceptScore W1976431529C121332964 @default.
• W1976431529 hasConceptScore W1976431529C121608353 @default.
• W1976431529 hasConceptScore W1976431529C126322002 @default.
• W1976431529 hasConceptScore W1976431529C141071460 @default.
• W1976431529 hasConceptScore W1976431529C143998085 @default.
• W1976431529 hasConceptScore W1976431529C167135981 @default.
• W1976431529 hasConceptScore W1976431529C2776326535 @default.
• W1976431529 hasConceptScore W1976431529C2776541429 @default.
• W1976431529 hasConceptScore W1976431529C2777251235 @default.
• W1976431529 hasConceptScore W1976431529C2777783956 @default.
• W1976431529 hasConceptScore W1976431529C2778231337 @default.
• W1976431529 hasConceptScore W1976431529C2779013556 @default.
• W1976431529 hasConceptScore W1976431529C2779399171 @default.
• W1976431529 hasConceptScore W1976431529C2780775167 @default.
• W1976431529 hasConceptScore W1976431529C530470458 @default.
• W1976431529 hasConceptScore W1976431529C61511704 @default.
• W1976431529 hasConceptScore W1976431529C71924100 @default.
• W1976431529 hasIssue "1" @default.
• W1976431529 hasLocation W19764315291 @default.
• W1976431529 hasLocation W19764315292 @default.
• W1976431529 hasOpenAccess W1976431529 @default.
• W1976431529 hasPrimaryLocation W19764315291 @default.
• W1976431529 hasRelatedWork W1515768733 @default.
• W1976431529 hasRelatedWork W2000999264 @default.
• W1976431529 hasRelatedWork W2350809060 @default.

• next